Ishitsuka, Kenji
Yurimoto, Satoshi
Kawamura, Kouichi
Tsuji, Yukie
Iwabuchi, Manabu
Takahashi, Takeshi
Tobinai, Kensei
Article History
Received: 7 February 2017
Revised: 29 May 2017
Accepted: 30 May 2017
First Online: 9 June 2017
Compliance with ethical standards
:
: KI reports grants and personal fees from Kyowa Hakko Kirin, Chugai Pharmaceutical, Takeda Pharmaceutical, Novartis, Eisai, and Taiho Pharmaceutical; personal fees from Bristol-Myers Squibb, Celgene, Janssen Pharmaceutical, and Pfizer; and grants from Yakult Pharmaceutical, MSD, and Japan Blood Products Organization, outside the submitted work. SY, KK, and YT are employees and stockholders of Kyowa Hakko Kirin. MI and TT are employees of Kyowa Hakko Kirin. KT reports grants and personal fees from Eisai, Takeda, Janssen, and Mundipharma; personal fees from Zenyaku Kogyo, and HUYA Bioscience International; and grants from Chugai Pharma, Kyowa Hakko Kirin, Ono Pharmaceutical Celgene, GlaxoSmithKline, SERVIER, and Abbvie, outside the submitted work.
: This study was funded by Kyowa Hakko Kirin Co., Ltd.
Free to read: This content has been made available to all.